Page 23/25 · Acute Kidney Injury & Kidney Replacement Therapy

Core Content

Acute Kidney Injury & Kidney Replacement Therapy

Paige Garber Bradshaw ~3 min read Module 9 of 20

/ 25

Acute Kidney Injury and Kidney Replacement Therapy in the Critically Ill Patient

Silver SA, Adhikari NK, Bell CM, et al. Nephrologist

follow-up versus usual care after an acute kidney injury

hospitalization (FUSION): a randomized controlled

trial. Clin J Am Soc Nephrol. 2021;16(7):1005-1014.

https://doi.org/10.2215/cjn.17331120

Teaford HR, Barreto JN, Vollmer KJ, Rule AD,

Barreto EF. Cystatin C: a primer for pharmacists.

Pharmacy (Basel). 2020;8(1):35. https://doi.org/10.3390/

pharmacy8010035

Uchino S, Kellum JA, Bellomo R, et al. Acute renal

failure in critically ill patients: a multinational, multi-

center study. JAMA. 2005;294(7):813-818. https://doi.

org/10.1001/jama.294.7.813

Zarbock A, Küllmar M, Ostermann M, et al.

Prevention of cardiac surgery-associated acute kid-

ney injury by implementing the KDIGO guidelines in

high-risk patients identified by biomarkers: the PrevAKI-

multicenter

randomized

controlled

trial.

Anesth

Analg.

2021;133(2):292-302.

https://doi.org/10.1213/

ane.0000000000005458

Kidney Replacement Therapies

Awdishu L, Bouchard J. How to optimize drug delivery

in renal replacement therapy. Semin Dial. 2011;24(2):176-

182. https://doi.org/10.1111/j.1525-139x.2011.00826.x

Bogard KN, Peterson NT, Plumb TJ, Erwin MW, Fuller

PD, Olsen KM. Antibiotic dosing during sustained

low-efficiency dialysis: special considerations in adult

critically ill patients. Crit Care Med. 2011;39(3):560-

570. https://doi.org/10.1097/ccm.0b013e318206c3b2

Bouajram RH, Awdishu L. A clinician’s guide to dosing

analgesics, anticonvulsants, and psychotropic medica-

tions in continuous renal replacement therapy. Kidney

Int Rep. 2021;6(8):2033-2048. https://doi.org/10.1016/j.

ekir.2021.05.004

Gaudry S, Palevsky PM, Dreyfuss D. Extracorporeal

kidney-replacement therapy for acute kidney injury.

N Engl J Med. 2022;386(10):964-975. https://doi.

org/10.1056/nejmra2104090

Hoff BM, Maker JH, Dager WE, Heintz BH. Antibiotic

dosing for critically ill adult patients receiving inter-

mittent hemodialysis, prolonged intermittent renal

replacement therapy, and continuous renal replacement

therapy: an update. Ann Pharmacother. 2020;54(1):43-

55. https://doi.org/10.1177/1060028019865873

Jaber S, Paugam C, Futier E, et al. Sodium bicarbon-

ate therapy for patients with severe metabolic acidaemia

in the intensive care unit (BICAR-ICU): a multicen-

tre, open-label, randomised controlled, phase 3 trial.

Lancet. 2018;392(10141):31-40. https://doi.org/10.1016/

s0140-6736(18)31080-8

Kanji S, Roger C, Taccone FS, Muller L. Practical

considerations for individualizing drug dosing in criti-

cally ill adults receiving renal replacement therapy.

Pharmacotherapy. 2023;43(11):1194-1205. https://doi.

org/10.1002/phar.2858

Tolwani A. Continuous renal-replacement therapy for

acute kidney injury. N Engl J Med. 2012;367(26):2505-

2514. https://doi.org/10.1056/nejmct1206045

Wald R, Bagshaw SM; STARRT-AKI Investigators.

Timing of initiation of renal-replacement therapy in acute

kidney injury. Reply. N Engl J Med. 2020;383(18):1797-

1798. https://doi.org/10.1056/nejmc2027489

Zarbock A, Küllmar M, Kindgen-Milles D, et al. Effect

of regional citrate anticoagulation vs systemic heparin

anticoagulation during continuous kidney replacement

therapy on dialysis filter life span and mortality among

critically ill patients with acute kidney injury: a ran-

domized clinical trial. JAMA. 2020;324(16):1629-1639.

https://doi.org/10.1001/jama.2020.18618

HD Video Explanation — Synchronized with PDF

Starts at: minute 22 Open on YouTube